iX Biopharma Ltd.

As of June 30, 2026, iX Biopharma Ltd. carries a market capitalization of 389.90M, placing it among publicly traded companies globally. Its enterprise value stands at 380.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, iX Biopharma Ltd. has 1.07B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, iX Biopharma Ltd. maintains a current ratio of 1.86, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, iX Biopharma Ltd. recorded 8,000.00 in income tax expense.

As of the close on October 22, 2026, iX Biopharma Ltd.'s stock has gained approximately 447.06% over the past 52 weeks. The 50-day moving average sits at 0.52, while the 200-day moving average is 0.36.

As of June 30, 2026, iX Biopharma Ltd. holds 14.74M in cash and equivalents against 5.80M in total debt, resulting in a net debt position of -9.39M. Total book value stands at 15.40M, with working capital of 8.61M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

iX Biopharma Ltd.'s most recent stock split took place on June 25, 2024 with a 965:976 split ratio.